Intensity TherapeuticsINTS +2.17%28 Buyback Yield % is -179.51 as of Jul. 03, 2026. GuruFocus rates INTS with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 744 Biotechnology companies, Intensity Therapeutics ranks worse than 94.49% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Intensity Therapeutics Buyback Yield % Related Terms
Intensity Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Intensity Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INTS vs KPRX, PHIO, PBM: Buyback Yield % Comparison
For the Biotechnology subindustry, Intensity Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intensity Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Intensity Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intensity Therapeutics (INTS) has a Buyback Yield % of -179.51 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Intensity Therapeutics and its competitors. According to the industry distribution chart, Intensity Therapeutics ranks #703 out of 744 companies in the Biotechnology industry, placing it in the top 94.5%.
Is Intensity Therapeutics' Buyback Yield % too high?
Intensity Therapeutics' current Buyback Yield % is -179.51. Based on the distribution chart, Intensity Therapeutics ranks #703 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Intensity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' Buyback Yield % compare to KPRX and PHIO?
According to the Biotechnology industry distribution chart, Intensity Therapeutics ranks #703 out of 744 companies for Buyback Yield %. This places Intensity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Intensity Therapeutics and its competitors. Intensity Therapeutics's current Buyback Yield % is -179.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current Buyback Yield % of -179.51. The current Buyback Yield % is -179.51. Intensity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current Buyback Yield % is -179.51 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score
Get the complete analysis for INTS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTS has been successfully added to your 
